yttrium radioisotopes has been researched along with Thrombopenia in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (9.68) | 18.2507 |
| 2000's | 15 (48.39) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cengel, KA; Damjanov, N; Metz, DC; Soulen, MC; Teitelbaum, UR; van Houten, D | 1 |
| Izumitani, S; Matsuo, H; Saeki, Y; Sakurashita, H; Taogoshi, T; Yoshikawa, H | 1 |
| Banerjee, A; Lam, MG; Louie, JD; Sze, DY | 1 |
| Botto, B; Carella, AM; Cascavilla, N; Ciabatti, E; Ciochetto, C; Fraternali Orcioni, G; Galimberti, S; Guolo, F; Ibatici, A; Nati, S; Orciuolo, E; Petrini, M; Pica, GM; Vitolo, U; Zinzani, PL | 1 |
| Andrade-Campos, MM; Baringo, T; Giraldo, P; Grasa, JM; Lopez-Gómez, L; Montes-Limón, AE; Soro-Alcubierre, G | 1 |
| Fabregas, JC; Goodman, D; Hoffman, JE; Hosein, PJ; Koru-Sengul, T; Lossos, IS; Miao, F; Rosenblatt, JD; Serafini, AN; Stefanovic, A | 1 |
| Midia, M | 1 |
| Arnason, JE; Avigan, D; Grant, B; Joyce, RM; Kim, M; Levine, J; Luptakova, K; Parker, JA; Rosenblatt, J; Tzachanis, D; Zwicker, JI | 1 |
| Bahary, N; Braiteh, FS; Bridges, BB; Cohen, SJ; Conkling, PR; Dragovich, T; Frank, RC; Goldenberg, DM; Goldsmith, SJ; Gribbin, TE; Guarino, MJ; Horne, H; Intenzo, CM; Korn, RL; Lee, FC; Lee, M; Lowery, MA; Manzone, TC; Mitchel, EP; O'Neil, BH; O'Reilly, EM; Ocean, AJ; Pandit-Taskar, N; Picozzi, VJ; Ramanathan, RK; Richards, DA; Sharkey, RM; Sheikh, A; Starodub, AN; Von Hoff, DD; Wegener, WA | 1 |
| Bondiau, PY; Broglia, JM; Carrier, P; Darcourt, J; Fontana, X; Gressin, R; Lepeu, G; Peyrade, F; Peyrottes, I; Slama, B; Thyss, A; Triby, C | 1 |
| Ferrajoli, A; Jain, N; Keating, M; Lerner, S; O'Brien, S; Wierda, W; Wong, F | 1 |
| Chen, YY; Soon, MS; Su, WW; Yang, CW; Yen, HH | 1 |
| Baechler, S; Bochud, FO; Hobbs, RF; Jacene, HA; Sgouros, G; Wahl, RL | 1 |
| Gaba, RC; Gundavaram, P | 1 |
| Bekaii-Saab, T; Gold, DV; Goldenberg, DM; Goldsmith, SJ; Guarino, MJ; Gulec, SA; Hall, N; Holt, M; Horne, H; Kauh, J; Lee, D; Manzone, T; Montero, AJ; O'Neil, BH; Ocean, AJ; Pennington, KL; Serafini, AN; Sheikh, A; Sung, MW; Wegener, WA | 1 |
| Duan, J; Khazaeli, MB; LoBuglio, AF; Macey, DJ; Meredith, RF; Robert, F; Shen, S | 1 |
| Bartlett, NL; Erwin, WD; Grillo-López, AJ; Leigh, BR; Podoloff, DA; Schilder, RJ; Sparks, RB; Spies, SM; White, CA; Wiseman, GA; Witzig, TE | 1 |
| Witzig, TE | 1 |
| Gregory, SA | 1 |
| Bartlett, NL; Blum, KA | 1 |
| Bartlett, N; Gordon, L; Molina, A; Murray, J; Schilder, R; Spies, S; Wang, H; White, C; Wiseman, G; Witzig, T | 1 |
| Dietlein, M; Engert, A; Eschner, W; Fischer, T; Pinkert, J; Schicha, H; Schnell, R; Schomäcker, K; Zimmermanns, B | 1 |
| Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabhajosula, S | 1 |
| Busby, E; Carey, D; Forero, A; Grizzle, WE; Khazaeli, MB; LoBuglio, AF; Meredith, RF; Robert, F; Shen, S | 1 |
| Balon, H; Brill, DR; Dillehay, GL; Ellerbroek, NA; Gaspar, LE; Grigsby, PW; Macklis, RM; Mauch, PM; Mian, TA; Potters, L; Silberstein, EB; Williams, TR; Wong, JC | 1 |
| Alinari, L; Baccarani, M; Bacci, F; Castellucci, P; de Vivo, A; Derenzini, E; Fanti, S; Farsad, M; Fina, M; Marchi, E; Musuraca, G; Pellegrini, C; Pileri, S; Stefoni, V; Tani, M; Zinzani, PL | 1 |
| Baer, HU; Becker, CD; Biasiutti, FD; Rösler, H | 1 |
| Behr, T; Blumenthal, RD; Goldenberg, DM; Haywood, L; Sharkey, RM | 1 |
| Adams, GP; Axworthy, D; Breitz, H; Bryan, K; Colcher, D; Fisher, DR; Gaffigan, S; Gentner, L; Goris, ML; Horak, ID; Knox, SJ; Tempero, M; Weiden, PL; Weiner, LM | 1 |
| Austin, JC; Gerstbrein, J; Kahn, D; Maguire, RT; Miller, SJ; Williams, RD | 1 |
| Allen, RS; Bartlett, NL; Gordon, LI; Grillo-López, AJ; Multani, PS; Murray, JL; Saleh, M; Schilder, RJ; Spies, S; White, CA; Wiseman, GA; Witzig, TE | 1 |
4 review(s) available for yttrium radioisotopes and Thrombopenia
| Article | Year |
|---|---|
Radioimmunotherapy in relapsed follicular lymphoma previously treated by autologous bone marrow transplant: a report of eight new cases and literature review.
Topics: Aged; Antibodies, Monoclonal; Bone Marrow Transplantation; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neutropenia; Radioimmunotherapy; Retrospective Studies; Salvage Therapy; Shock, Septic; Thrombocytopenia; Transplantation, Autologous; Treatment Outcome; Yttrium Radioisotopes | 2008 |
Efficacy and safety of 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy for non-Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Recurrence; Risk Factors; Thrombocytopenia; Yttrium Radioisotopes | 2003 |
Selecting patients for treatment with 90Y ibritumomab tiuxetan (Zevalin).
Topics: Antibodies, Monoclonal; Antigens, CD20; Humans; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Neutropenia; Patient Selection; Thrombocytopenia; Yttrium Radioisotopes | 2003 |
90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma.
Topics: Animals; Antibodies, Monoclonal; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Forecasting; Humans; Immunoconjugates; Lymphoma, Non-Hodgkin; Mice; Neutropenia; Radioimmunotherapy; Radiotherapy Dosage; Thrombocytopenia; Treatment Outcome; Yttrium Radioisotopes | 2004 |
14 trial(s) available for yttrium radioisotopes and Thrombopenia
| Article | Year |
|---|---|
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Female; Humans; Lymphoma, Follicular; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pilot Projects; Radiation Injuries; Radioimmunotherapy; Remission Induction; Survival Analysis; Thrombocytopenia; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Fatigue; Female; Fever; Humans; Kaplan-Meier Estimate; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Radioimmunotherapy; Remission Induction; Thrombocytopenia; Treatment Outcome; Yttrium Radioisotopes | 2015 |
(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Chemotherapy, Adjuvant; Deoxycytidine; Disease Progression; Feasibility Studies; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucins; Pancreatic Neoplasms; Radioimmunotherapy; Radiopharmaceuticals; Remission Induction; Thrombocytopenia; Time Factors; Treatment Outcome; United States; Yttrium Radioisotopes | 2015 |
A phase 2 study of yttrium-90 ibritumomab tiuxetan (Zevalin) in patients with chronic lymphocytic leukemia.
Topics: Aged; Antibodies, Monoclonal; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Radioimmunotherapy; Remission Induction; Thrombocytopenia; Yttrium Radioisotopes | 2009 |
Fractionated radioimmunotherapy with (90) Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer: A phase 1 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Pancreatic Neoplasms; Radiation Dosage; Radiation-Sensitizing Agents; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2012 |
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
Topics: Adult; Aged; Animals; Antigens, Neoplasm; Bone Marrow; Carcinoma, Non-Small-Cell Lung; Glycoproteins; Humans; Indium Radioisotopes; Lumbar Vertebrae; Lung Neoplasms; Mice; Middle Aged; Radiation Dosage; Radioimmunotherapy; Radiometry; Thrombocytopenia; Yttrium Radioisotopes | 2002 |
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia.
Topics: Adolescent; Antibodies, Monoclonal; Antigens, CD20; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Lymphoma, Non-Hodgkin; Radioimmunotherapy; Radiometry; Salvage Therapy; Thrombocytopenia; Tissue Distribution; Tomography, Emission-Computed; Treatment Outcome; Yttrium Radioisotopes | 2003 |
Follow-up results of a phase II study of ibritumomab tiuxetan radioimmunotherapy in patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma and mild thrombocytopenia.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antigens, CD20; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Thrombocytopenia; Yttrium Radioisotopes | 2004 |
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity.
Topics: Antibodies, Monoclonal; Blood Platelets; Bone Marrow; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Lutetium; Male; Maximum Tolerated Dose; Prostate-Specific Antigen; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Thrombocytopenia; Time Factors; Yttrium Radioisotopes | 2005 |
Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: effect of chelating agents and paclitaxel co-administration.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chelating Agents; Clinical Trials as Topic; Disease Progression; Edetic Acid; Female; Glycoproteins; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neutropenia; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radiometry; Thrombocytopenia; Treatment Outcome; Up-Regulation; Yttrium Radioisotopes | 2005 |
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Feasibility Studies; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Neutropenia; Prednisone; Prognosis; Prospective Studies; Radioimmunotherapy; Remission Induction; Thrombocytopenia; Treatment Outcome; Vincristine; Yttrium Radioisotopes | 2008 |
Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer.
Topics: Adult; Aged; Anemia; Antibodies, Monoclonal; Biotin; Colonic Neoplasms; Female; Humans; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Radioimmunotherapy; Radiopharmaceuticals; Thrombocytopenia; Yttrium Radioisotopes | 2000 |
A phase II study of [90Y] yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Marrow; Combined Modality Therapy; Edetic Acid; Gonadotropin-Releasing Hormone; Humans; Immunoconjugates; Leukopenia; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiation Injuries; Radioimmunodetection; Salvage Therapy; Soft Tissue Neoplasms; Thrombocytopenia; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Yttrium Radioisotopes | 1999 |
Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Combined Modality Therapy; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radiation Dosage; Radioimmunotherapy; Remission Induction; Salvage Therapy; Thrombocytopenia; Tissue Distribution; Treatment Outcome; Yttrium Radioisotopes | 2002 |
13 other study(ies) available for yttrium radioisotopes and Thrombopenia
| Article | Year |
|---|---|
Safety and Feasibility of Integrating Yttrium-90 Radioembolization With Capecitabine-Temozolomide for Grade 2 Liver-Dominant Metastatic Neuroendocrine Tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neuroendocrine Tumors; Temozolomide; Thrombocytopenia; Yttrium Radioisotopes | 2018 |
Safety of
Topics: Aged; Aged, 80 and over; Anemia; Antibodies, Monoclonal; Asian People; Female; Humans; Japan; Leukopenia; Lymphoma; Male; Middle Aged; Neutropenia; Radiopharmaceuticals; Retrospective Studies; Safety; Thrombocytopenia; Treatment Outcome; Yttrium Radioisotopes | 2019 |
Splenomegaly-associated thrombocytopenia after hepatic yttrium-90 radioembolization.
Topics: Adult; Aged; Aged, 80 and over; Diagnostic Imaging; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Radiotherapy Dosage; Retrospective Studies; Splenomegaly; Survival Rate; Thrombocytopenia; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Long-term efficacy of (90)Y ibritumomab tiuxetan therapy in follicular non-Hodgkin lymphoma and health-related quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antibody-Dependent Cell Cytotoxicity; Antigens, CD20; Antigens, Neoplasm; Disease-Free Survival; Drug Evaluation; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphoma, Follicular; Male; Middle Aged; Neoplasms, Multiple Primary; Neoplasms, Second Primary; Neutropenia; Quality of Life; Radioimmunotherapy; Remission Induction; Rituximab; Thrombocytopenia; Yttrium Radioisotopes | 2014 |
Spleen: promised land for new and novel interventions?
Topics: Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Splenomegaly; Thrombocytopenia; Yttrium Radioisotopes | 2015 |
Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Disease-Free Survival; Follow-Up Studies; Humans; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Radioimmunotherapy; Remission Induction; Rituximab; Salvage Therapy; Survival Rate; Thrombocytopenia; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2015 |
Profound transient thrombocytopenia associated with 90Yttrium microsphere therapy for inoperable hepatoma.
Topics: Aged; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Microspheres; Thrombocytopenia; Yttrium Radioisotopes | 2010 |
Predicting hematologic toxicity in patients undergoing radioimmunotherapy with 90Y-ibritumomab tiuxetan or 131I-tositumomab.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal; Bone Marrow; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Leukocyte Count; Linear Models; Lymphoma, Non-Hodgkin; Male; Middle Aged; Models, Statistical; Neutrophils; Platelet Count; Predictive Value of Tests; Radioimmunotherapy; Radiometry; Radiopharmaceuticals; Thrombocytopenia; Yttrium Radioisotopes | 2010 |
Thrombocytopenia following 90Yttrium glass microsphere liver radioembolization.
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Liver Neoplasms; Microspheres; Platelet Count; Thrombocytopenia; Yttrium Radioisotopes | 2011 |
[Radioimmunotherapy with yttrium-90 ibritumomab tiuxetan. Clinical considerations, radiopharmacy, radiation protection, perspectives].
Topics: Anemia; Antibodies, Monoclonal; Chromatography, High Pressure Liquid; Humans; Lymphoma; Neutropenia; Quality Control; Radiation Protection; Radioimmunotherapy; Radionuclide Imaging; Thrombocytopenia; Yttrium Radioisotopes | 2005 |
Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources.
Topics: Antibodies, Monoclonal; Ascites; Bone Neoplasms; Chromium Compounds; Humans; Hyperthyroidism; Iodine Radioisotopes; Lymphoma, Non-Hodgkin; Organometallic Compounds; Organophosphorus Compounds; Pain; Patient Isolation; Phosphates; Pleural Effusion, Malignant; Polycythemia Vera; Radiation Protection; Radiopharmaceuticals; Sodium Iodide; Strontium Radioisotopes; Thrombocytopenia; Thyroid Neoplasms; Yttrium Radioisotopes | 2006 |
Congestive hypersplenism: treatment by means of radioembolization of the spleen with Y-90.
Topics: Aged; Brachytherapy; Follow-Up Studies; Humans; Hypersplenism; Male; Microspheres; Spleen; Thrombocytopenia; Time Factors; Tomography, X-Ray Computed; Yttrium Radioisotopes | 1995 |
Application of cytokine intervention for improved radio-antibody dose delivery.
Topics: Animals; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Immunoglobulin Fab Fragments; Immunoglobulin G; Interleukin-1; Iodine Radioisotopes; Leukocyte Count; Mice; Mice, Inbred BALB C; Neutropenia; Radioimmunotherapy; Rhenium; Thrombocytopenia; Yttrium Radioisotopes | 1997 |